Figure S3 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Publication
, Other
Crosby, EJ; Acharya, CR; Haddad, A-F; Rabiola, CA; Lei, G; Wei, J-P; Yang, X-Y; Wang, T; Liu, C-X; Wagner, KU; Muller, WJ; Chodosh, LA; He, X ...
March 31, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Crosby, E. J., Acharya, C. R., Haddad, A.-F., Rabiola, C. A., Lei, G., Wei, J.-P., … Hartman, Z. C. (2023). Figure S3 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. https://doi.org/10.1158/1078-0432.22477278.v1
Crosby, Erika J., Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, et al. “Figure S3 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22477278.v1.
Crosby EJ, Acharya CR, Haddad A-F, Rabiola CA, Lei G, Wei J-P, et al. Figure S3 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 2023.
Crosby, Erika J., et al. Figure S3 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22477278.v1.
Crosby EJ, Acharya CR, Haddad A-F, Rabiola CA, Lei G, Wei J-P, Yang X-Y, Wang T, Liu C-X, Wagner KU, Muller WJ, Chodosh LA, Broadwater G, Hyslop T, Shepherd JH, Hollern DP, He X, Perou CM, Chai S, Ashby BK, Vincent BG, Snyder JC, Force J, Morse MA, Lyerly HK, Hartman ZC. Figure S3 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 2023.